RNA 腫瘍療法:細胞内ヘアピン RNA アセンブリはマイクロRNA 誘発抗がん機能を可能にします.
PubMedで要約を見る
まとめ
この要約は機械生成です。研究者らは,がん細胞を選択的に標的にし,殺す新しい発酵性RNAヘアピンペア (oHP) を開発しました. このRNA治療薬は,腫瘍性マイクロRNA-21によって活性化され,抗がん剤として作用する.
科学分野
- 生物化学
- 分子生物学
- RNAセラピー
背景
- RNA療法では 生物分子を多用途に利用できます
- 長い二重鎖RNA (dsRNA) は,免疫活性化抗腫瘍剤としての可能性を示しています.
- 現在のdsRNA治療は,がんの選択性と細胞浸透性において課題に直面しています.
研究 の 目的
- 新しい腫瘍解析RNAヘアピンペア (oHP) を設計し合成する.
- マイクロRNA-21 (miR-21) を発現する癌細胞に対する選択的細胞毒性を達成する.
- 腫瘍性miRNAによって誘発される抗がん剤を開発する.
主な方法
- 熱力学的にメタスタブルなオンコリティックRNAヘアピンペア (oHP) の設計と合成.
- miR-21によって誘発されたoHPの触媒的な開きが,長い切断されたdsRNAを形成することを示す.
- がん細胞と腫瘍を患ったマウスにおけるoHPのインビトロおよびインビボ試験.
主要な成果
- oHPは,高いmiR- 21発現を持つ癌細胞に対して選択的に毒性を示した.
- miR-21は,oHPの開きを誘発し,長く切断されたdsRNAを生成しました.
- oHPは様々ながんモデルでmiR-21の存在で細胞毒性増強剤として作用した.
結論
- この研究は,腫瘍性miRNAによって誘発される短いRNA分子を用いた最初の蓄積型抗がん剤を導入した.
- oHPは選択的に癌細胞を殺し,RNA治療薬としての潜在能力を示しています.
- このアプローチは,従来のdsRNA抗腫瘍剤の限界を克服します.
関連する概念動画
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

